Cassia auriculata is an important medicinal herb traditionally used for the treatment and management of diabetes. Scientific research has reported some bioactivities related to traditional roles that include antihyperglycemic and antihyperlipidemic, which could inhibit onset of diabetes. Our aim was twofold: To review the presence of phytochemical compounds in plant extracts and to perform an in-papyro evaluation of their antidiabetic potential. A detailed literature survey was carried out for evaluating metabolic syndrome-related medicinal bioactivities and antidiabetic activity from specific compounds of C. auriculata. We uncovered a wide range of medicinal uses of C. auriculata in Ayurveda and Sri Lankan medicinal traditions and cultures. Many of the compounds in C. auriculata extracts have already been reported for their specific antidiabetic, hypoglycemic, and hypolipidemic activities, which exhibited positive effects on neuro, renal, and liver support. In conclusion, our findings suggested that the phytocomposition of C. auriculata could be attributed to the presence of antidiabetic activity through various mechanisms.
Citation: Zipora Tietel, Devanesan Arul Ananth, Thilagar Sivasudha, Liron Klipcan. Cassia auriculata L.–A mini review of phytochemical compounds and their antidiabetic mechanisms[J]. AIMS Agriculture and Food, 2024, 9(1): 374-392. doi: 10.3934/agrfood.2024022
Related Papers:
[1]
Maeve L. McCarthy, Dorothy I. Wallace .
Optimal control of a tick population with a view to control of Rocky Mountain Spotted Fever. Mathematical Biosciences and Engineering, 2023, 20(10): 18916-18938.
doi: 10.3934/mbe.2023837
[2]
Rocio Caja Rivera, Shakir Bilal, Edwin Michael .
The relation between host competence and vector-feeding preference in a multi-host model: Chagas and Cutaneous Leishmaniasis. Mathematical Biosciences and Engineering, 2020, 17(5): 5561-5583.
doi: 10.3934/mbe.2020299
[3]
Yan-Xia Dang, Zhi-Peng Qiu, Xue-Zhi Li, Maia Martcheva .
Global dynamics of a vector-host epidemic model with age of infection. Mathematical Biosciences and Engineering, 2017, 14(5&6): 1159-1186.
doi: 10.3934/mbe.2017060
[4]
Yunbo Tu, Shujing Gao, Yujiang Liu, Di Chen, Yan Xu .
Transmission dynamics and optimal control of stage-structured HLB model. Mathematical Biosciences and Engineering, 2019, 16(5): 5180-5205.
doi: 10.3934/mbe.2019259
Djamila Moulay, M. A. Aziz-Alaoui, Hee-Dae Kwon .
Optimal control of chikungunya disease: Larvae reduction, treatment and prevention. Mathematical Biosciences and Engineering, 2012, 9(2): 369-392.
doi: 10.3934/mbe.2012.9.369
[7]
Fahad Al Basir, Yasuhiro Takeuchi, Santanu Ray .
Dynamics of a delayed plant disease model with Beddington-DeAngelis disease transmission. Mathematical Biosciences and Engineering, 2021, 18(1): 583-599.
doi: 10.3934/mbe.2021032
[8]
Ling Xue, Caterina Scoglio .
Network-level reproduction number and extinction threshold for vector-borne diseases. Mathematical Biosciences and Engineering, 2015, 12(3): 565-584.
doi: 10.3934/mbe.2015.12.565
[9]
Rundong Zhao, Qiming Liu, Huazong Zhang .
Dynamical behaviors of a vector-borne diseases model with two time delays on bipartite networks. Mathematical Biosciences and Engineering, 2021, 18(4): 3073-3091.
doi: 10.3934/mbe.2021154
[10]
Rong Ming, Xiao Yu .
Global dynamics of an impulsive vector-borne disease model with time delays. Mathematical Biosciences and Engineering, 2023, 20(12): 20939-20958.
doi: 10.3934/mbe.2023926
Abstract
Cassia auriculata is an important medicinal herb traditionally used for the treatment and management of diabetes. Scientific research has reported some bioactivities related to traditional roles that include antihyperglycemic and antihyperlipidemic, which could inhibit onset of diabetes. Our aim was twofold: To review the presence of phytochemical compounds in plant extracts and to perform an in-papyro evaluation of their antidiabetic potential. A detailed literature survey was carried out for evaluating metabolic syndrome-related medicinal bioactivities and antidiabetic activity from specific compounds of C. auriculata. We uncovered a wide range of medicinal uses of C. auriculata in Ayurveda and Sri Lankan medicinal traditions and cultures. Many of the compounds in C. auriculata extracts have already been reported for their specific antidiabetic, hypoglycemic, and hypolipidemic activities, which exhibited positive effects on neuro, renal, and liver support. In conclusion, our findings suggested that the phytocomposition of C. auriculata could be attributed to the presence of antidiabetic activity through various mechanisms.
1.
Introduction
Vector-borne diseases exhibit a common feature: a two-way transmission of the pathogen between human hosts and various species of arthropods, most often mosquitos, that serve as carriers (or vectors) of the pathogen, but direct host-host transmission is impossible for most of them. Diseases caused by pathogens transmitted by mosquito bites (malaria, dengue fever, yellow fever, zika, chikungunya) cause periodic outbreaks in the countries located in tropical climate zones, and pose a growing burden on their healthcare systems, as seen, for instance, in a 30-fold increase in dengue fever's incidence since the 1970s [1]. Control campaigns against them are based on two broad types of measures: suppression of transmission and elimination of the vector. They rely on the use of long-lasting insecticidal nets (LLINs), indoor residual spraying with insecticide, use of larvicide, as well as use of personal protection means with repellent activity that include spray-on repellents or repellent-treated textiles and household items.
The success of control measures aimed at the vector's demography, like bed nets and insecticide spraying, in reducing the disease burden has been limited for various reasons. On the one hand, there is evidence for changing patterns in the transmission of malaria to outdoor environments [2,3,4,5], while the main vectors of dengue, yellow fever and zika viruses, female mosquitoes of the Aedes genus are active during daytime hours. Indiscriminate use of insecticide and larvicide, on the other hand, poses danger to human health and the ecosystem. Furthermore, insecticide resistance has contributed to the failure of the Global Malaria Eradication Programme [6] and has been noted among Aedes mosquitos [7,8].
Use of repellent-treated clothes and household items as preventive measure could serve to suppress transmission of pathogens from vector to host and vice versa. Changing mosquito host-seeking behavior by repellent application could reduce the biting rate of the female mosquitoes, and this strategy has gained attention among entomologists. This includes studies of the effect of spray-on repellents and wearable repellent devices on mosquito host-seeking behavior [9], and tests of fibers for controlled release of volatile mosquito repellents to prevent bites in the context of malaria control [10]. Development of mosquito repellents based on organic substances from plant oils [11], and of methods for estimation of efficacy of repellents used in textiles and paints [12] reveal new perspectives for such measures.
Mathematical modeling can help analyze and predict the performance of such interventions for meeting policy objectives. We study a simple Ross-Macdonald type model[6] for a vector-borne disease with control based on distribution of textiles and household items with repellent properties. The constraints on an intervention campaign of this kind encompass, first, the economic cost of production, distribution, etc. of the repellent-treated textiles, which influences its extent, that is, the maximum fraction ˉu of the target population employing products with mosquito repellent property. Second, due to technological and physical limitations, such as evaporation, washing, UV radiation exposure, etc., the repellent property is assumed to be lost after a period of durationT days..
In this study we propose a method to analyze whether a control campaign under those constraints is able to reduce and maintain the size of the infected host compartment below a certain level, denoted henceforth as the infection cap.
The infection capˉI is a constraint on a state variable of the model (infected hosts) and its value depends on factors, such as the availability of treatment, healthcare system capacity or societal or political tolerances, etc. For the purpose of our analysis, we state the following Questions.
Q.1 Given ˉu,ˉI and initial data on infected hosts and vectors, establish whether the size of the infected host compartment can remain below the infection cap for all future times and find the optimal strategy to maintain it.
Q.2 If the initial data are such that the objective from Q.1 can not be met, we address the following: given ˉu,ˉI,T, find the optimal strategy to bring the size of the infected host compartment below the infection cap ˉI in a minimal time not exceeding T, and maintain it below the cap ˉI until the campaign's end.
Both questions concern characterization of initial data inside the model's state space unlike standard control analysis in the context of vector-borne diseases, which addresses optimal resource allocation [13,14,15,16] These questions can be addressed using the toolbox of optimal control theory.
Question Q.1 is a viability problem and we study the existence of viable trajectories of the dynamical system, namely those that satisfy the constraint stated in Q.1. The maximum set of initial data for Q.1 where this constraint is met, is the viability kernel. There has been some analysis of viable controls in epidemiology: in reference [17] viability kernels for a model with control on the mosquito population by fumigation have been computed and validated with data from a dengue outbreak in Cali, Colombia. In a previous work [18] we have characterized the viability kernel of a model for a vector-borne disease with susceptible, infected and removed compartments for the host population. Even though this problem has an infinite time horizon, its solution shall be used for the solution of Question Q.2.
For Question Q.2 we study a reachability problem for a target set (the viability kernel), and compute the minimal entry time function to it. Such analysis can serve as a guide to policy makers to determine determine whether and how fast the repellent-based control campaign constrained by its coverage ˉu and duration T is able to reduce the size of the infected host compartment below the infection cap ˉI. If the minimal time lies within the given time horizon (0,T), the campaign is considered effective. Else, the campaign should be considered ineffective because it cannot meet this objective. The reachability problem framed by Question Q.2 is important as it can provide an indicator of the control campaign's performance under the constraints to decision makers.
We use a variational approach to compute numerically approximations of the viability kernel of the controlled system and the minimal entry time function to the viability kernel, using sub-zero level set of a value function solving a Hamilton-Jacobi equation associated to the model system. The viability kernel can also be described analytically by its boundary in the phase plane of the state variables (infected hosts and infected vectors) [17]. However, the numerical approximation of the value function from the variational approach {allows us} to reconstruct the control function which solves the viability and reachability problems. We illustrate the application of this method from optimal control theory using parameterized models for malaria transmission in Botswana and Zimbabwe [19] and discuss the efficacy of the repellent-based control campaign in meeting the stated objectives.
2.
Mathematical model
We use the compartmental model for a vector-borne disease as presented in [20], which follows the dynamics of susceptible and infected hosts Sh(t),Ih(t) and susceptible and infected female mosquitoes Sv(t),Iv(t) that serve as vectors for the pathogen, at time t≥0. Susceptible hosts become infected after receiving a bite from an infectious mosquito. A susceptible mosquito becomes infected after biting an infected host, and after an incubation period of length τ becomes infectious and is able to transmit the pathogen. We model the incubation period without a specific compartment as done by [19,21]. If the within-vector incubation period τ and the expected life-time of a mosquito 1/μ are of the same order of magnitude, the probability of death of an infected mosquito during the pathogen incubation is not negligible. Hence, merely a fraction exp(−μτ) of the infected mosquitoes Iv is capable of transmitting the pathogen to the host [21]. In this model no protective immunity is assumed. Hosts from the infected compartment after a short infectious period re-enter immediately the susceptible compartment [22,23], the length of the period is 1/γ, with γ the recovery rate.
Let u(t) denote the proportion of the target population at time t using the measures provided by the control campaign. With k being the repellent efficacy, the modified mosquito biting rate due to use of control measures is am(1−ku(t)). Such modified infection rates are used in reference [15] in the context of an age-structured model for malaria and controls by long-lasting insecticidal nets. We assume that the cost of control effort C(u(t)) (production and distribution of the repellent-treated textiles or spray-on repellents) is borne by decision makers and is a linear function of u(t) (compare reference [38]), and that C(u(t))≤Cmax for all t≥0. This means that u(t)≤ˉu for all t≥0 for some maximum coverage ˉu∈(0,1] of the target population. The set of control functions we consider is
U={u(t):R+→[0,ˉu],u−piecewise continuous }.
Observe that for u=ˉu we have the maximum available reduction of the biting rate, while for u=0 there is no control used, and hence no reduction of the biting rate.
The host population is assumed to be constant over time, Sh(t)+Ih(t)=N. We assume that the repellent-based control does not lead to changes in the total populations of female mosquitoes over time, M=Sv(t)+Iv(t). Hence, we can reduce the number of state variables by letting Sh=N−Ih,Sv=M−Iv and non-dimensionalizing x1=Ih/N,x2=Iv/M. In our notation, x(t) denotes the vector of state variables describing the different compartments of the epidemiological model at time t, and f(x,u) denotes the model dynamics subject to a control function u∈U.
Letting ν=M/N be the average number of female mosquitoes per host and setting for shortness's sake α=amphexp(−μτ),β=ampv, we work with the 2-dimensional non-autonomous system:
subject to initial conditions x0=(x1(0),x2(0))∈Ω=[0,1]2. The domain of definition Ω corresponds to the states x with relevant epidemiological meaning for (2.1). On the segments on the boundary ∂Ω defined by x1=0,x2=0,x2=1,x1=1, one can verify that the flow defined by f points towards intΩ. Thus, Ω is forward invariant under f.
The associated trajectory of (2.1) for a given control function u∈U with initial condition x0 will be denoted by xu(t;x0)={(xu1(t),xu2(t)),t>0}. The set of feasible trajectories on the time interval [0,+∞) starting at x0∈Ω at time t=0 will be denoted by
S(x0,U):={xu(t;x0)|u∈U}.
The system (2.1) is cooperative (or quasimonotone[20]) because ∂xifj≥0,i≠j. Hence, tools from the theory of ordinary differential equations such as comparison principles [24] are at our disposal to establish properties of the feasible trajectories.
We conclude this section with
Lemma 1.The function f in system (2.1) is Lipschitz continuous on Ω with Lipschitz constant
L=[(max{2αν,αν+γ})2+(max{2β,β+μ})2]1/2
(2.2)
Proof. The estimate follows from direct computation of the Euclidean norm for |f(x,u)−f(x′,u′)|,x,x′∈Ω,u,u′∈[0,ˉu].
Using the Lipschitz continuity of f on Ω (Lemma 1) as well as the facts that a) the set {f(x,u),0≤u≤ˉu} is convex for all x∈Ω and b) we can choose C>0 so f(x,u)≤C(1+|x|) on Ω (f has linear growth), we establish that solutions to system (2.1) exist for t≥0 [25,Chapter III.5]. In addition, since the domain and graph of f are closed, f is a Marchaud map on Ω [26,Corollary 2.2.5].
3.
Viability analysis
In Question Q.1 we are interested in finding the initial conditions x0 of (2.1) such that for a given maximum extent ˉu and infection cap ˉI>0, there exists u(t)∈U such that xu1(t)≤ˉI,∀t≥0. Let A(ˉI)={(x1,x2)∈Ω|x1≤ˉI}, which is a closed subset of Ω with a compact boundary. A feasible trajectory x∈S(x0,U) is called viable for A(ˉI) if the constraint xu1(t)≤ˉI,∀t≥0 is met, in other words, x(t)∈A(ˉI) for t∈[0,+∞]. A set D⊂Ω is a viability domain for f if from any initial state x0∈D, at least one trajectory x∈S(x0,U) is viable for D[26,27].
To answer Question Q.1, we characterize the viability kernel associated to AˉI,ˉu, that is the following set of initial data for (2.1):
V(ˉI,ˉu):={x0∈Ω|∃x∈S(x0,U) with x(t)∈A(ˉI),∀t≥0}.
(3.1)
Evidently, V(ˉI,ˉu) is the set of all initial data x0∈A(ˉI) from which viable trajectories for A(ˉI) for t≥0 exist. It is the largest closed viability domain of f inside A(ˉI)[27]. The set A(ˆI) being closed, and f being a Marchaud map, the viability kernel V(ˉI,ˉu) for system (2.1) is well-defined [26,Theorem 4.1.2]. The viability kernel will depend on the constraint on the control ˉu, and on the state constraint (the infection cap ˉI).
We introduce the effective basic reproduction number for control intervention u(t)≡ˉu
Rˉu=αβν(1−k˜u)2γμ
(3.2)
and the critical threshold of infection
Icrit=Rˉu−1Rˉu+βμ(1−kˉu),
(3.3)
whenever Rˉu>1,Icrit>0. Following reference [18], Icrit equals the share of infected hosts at the endemic equilibrium E∗ of system (3.4) at the maximum coverage with repellent-treated products.
Here we briefly recall stability properties of the model equilibria under constant controls u(t)=ˉu. In that case the system (2.1) becomes autonomous,
System (3.4) has a trivial, disease-free equilibrium at the origin O and an endemic equilibrium:
E∗=(x∗1,x∗2)=(Icrit,Rˉu−1Rˉu+ανγ(1−kˉu)).
(3.5)
Note that E∗∈intΩ* if and only if Rˉu>1. At Rˉu=1, a transcritical bifurcation occurs and E∗ and O coincide [23].
*By intX we denote the interior of a set X.
Lemma 2.The system (3.4) has the following asymptotic behavior:
(i) Rˉu≤1 implies that the disease-free equilibrium O is globally asymptotically stable for (3.4) in Ω.
(ii) Rˉu>1 implies that the endemic equilibrium E∗ (3.5) is globally asymptotically stable for (3.4) in Ω∖O.
The proofs of Lemma 2 and further statements are in the Supplementary Material.
Using ˉI and Icrit, we characterize whether the viability kernel for system (2.1) has a positive Lebesgue measure in R2:
Proposition 1.Consider the model with constant vector population (2.1). Let
(i) ˉI≥max{0,Icrit}. Then intV(ˉI,ˉu) has positive Lebesgue measure in R2.
(ii) Icrit>0 and ˉI<Icrit. Then V(ˉI,ˉu)=O.
Based on Proposition 1, the description of V(ˉI,ˉu) can be refined by defining its boundaries. This has been the approach in reference [17], and we recall the details for model (2.1). We start by a technical result:
Lemma 3.Let ˉI>max{0,Icrit}. Set ˉv=γˉIαν(1−kˉu)(1−ˉI) and assume ˉv<1.The initial value problem
has a unique non-negative solution which is monotone decreasing on the interval (ˉv,min{1,v∗}), where v∗ is such that z(v∗)=0.
Due to the inverse function theorem, Lemma 3 implies the existence of an inverse map z−1 to z defined on [0,ˉI] such that z−1(z(s))=s. We denote by Z the solution curve (z(s),s) in Ω of the problem in Lemma 3 to describe explicitly the boundary of the viability kernel for the case ˉI>max{0,Icrit}.
Proposition 2.For given ˉI,ˉu the viability kernel V(ˉI,ˉu) takes one of the following forms
(i) Let ˉI>(1−kˉu)αν(1−kˉu)αν+γ, then V(ˉI,ˉu)=A(ˉI).
(ii) Let ˉI∈(max{0,Icrit},(1−kˉu)αν(1−kˉu)αν+γ]. Then
where z(x) is the solution to the initial value problem (3.6) in Lemma 3, and v∗ such that z(v∗)=0.
Unfortunately, this "direct" approach does not work for the case ˉI=Icrit. While Proposition 1 shows that the viability kernel has positive measure, the approach from Lemma 3 cannot work, because the right-hand side of (3.6) is not defined at the initial condition z(ˉv)=ˉI, which is precisely at the endemic equilibrium E∗.
To avoid this problem, we state an alternative characterization of the viability kernel using a variational formulation. Following reference [28], we consider an infinite horizon minimization problem with exact penalization of the state constraint. The constraint is expressed via the cost function, defined by the signed distance function Γ
Note that Γ(x)≤0 if and only if x∈A(ˉI). Following the steps in reference [28], we consider for ℓ>0 the value function
v(x)=infu∈Usupt∈(0,+∞)e−ℓtΓ(xu(t;x)),x∈R2.
(3.9)
Note that v takes finite values on Ω. From (3.9), it follows v(x)≤0 if and only if xu(t;x)∈V(ˉI,ˉu) for all t∈(0,+∞). Therefore, the viability kernel may be characterized using sub-zero-level sets of the value function v:
V(ˉI,ˉu)={x∈Ω|v(x)≤0}.
(3.10)
Let ℓ>L with L being the Lipschitz constant of f (Lemma 1). Then the value function v satisfies the following dynamic programming principle
Let ∇v denote the gradient of v, ∇v=(∂x1v,∂x2v). The results in reference [28,Section 4] imply that v is the unique continuous viscosity solution [33,Definition 2] of the Hamilton-Jacobi-Bellman equation
min{ℓv(x)+maxu∈UH(x,u,∇v),v(x)−Γ(x)}=0,x∈R2.
(3.11)
with ℓ as above and Hamiltonian
H(x,u,∇v)=⟨−f(x,u),∇v⟩.
(3.12)
We refer the reader to reference [25,Chapter 1.3] for the definitions of viscosity solutions to partial differential equations.
Hence, using well-known numerical methods for Hamilton-Jacobi equations based on finite difference discretization of the spatial derivative [29,30], one can compute the solution of (3.11) and find an approximation of the viability kernel V(ˉI,ˉu) for given values of target infection cap ˉI and maximum coverage ˉu.
In our case the quantity maxu∈UH(x,u,∇v) has an explicit form :
Using the computed value function v, we can answer Q.1, compute the optimal control function u(t) and reconstruct the optimal trajectory for a given initial condition x0∈V(ˉI,ˉu) using the reconstruction algorithm from reference [31,32]. This algorithm is applied in reference [18] to approximate the viability kernel for another model of a vector-borne disease.
4.
Minimal entry time problem
Once we have computed the viability kernel, we turn our attention to the reachability problem from Question Q.2. Let the initial data x0=(x1(0),x2(0)) on infected hosts and vectors, the maximum extent ˉu, the duration T, and the infection cap ˉI be given. We ask if there exists an optimal strategy u(t) to bring x1 population below the infection cap ˉI in a minimal time τ<T and maintain x1(t)<ˉI for t∈(τ,T].
To this purpose we define the minimal entry time functionTX(x) for initial data x to the target set X as follows:
TX(x)={+∞, if {t≥0|xu(t;x)∈X}=∅,infu∈Umin{t≥0|xu(t;x)∈X},else.
(4.1)
The objective in Question Q.2 is to compute the minimal entry time function for the target set being the viability kernelV(ˉI,ˉu). This makes sense unless the viability kernel is trivial (in other words, we are interested in computing T for V(ˉI,ˉu)≠O). By definition, V(ˉI,ˉu)⊂Ω is a compact set, hence ∂V(ˉI,ˉu) is compact. We shall characterize the minimal entry time function using the value function v from (3.9) based on the approach presented in references [28,33].
Using the value function v which solves (3.11) and defines the viability kernel V(ˉI,ˉu) via its sub-zero level set (3.10) from the previous section we formulate a variational problem for the minimal entry time function. The backwards reachable set for the target set (which is viability kernel V(ˉI,ˉu)) at time T, denoted by W(T), is defined as the set of those initial data x for system (2.1) such that there exists a feasible trajectory x∈S(x,U) with xu(t;x)∈V(ˉI,ˉu) for t≤T.
In other words,
W(T)={x∈R2|∃t∈[0,T],u∈U:xu(t;x)∈V(ˉI,ˉu)}.
(4.2)
Note that {W(t),t≥0} is a family of increasing closed sets [33,Remark 2]. We remark that even though the biologically relevant domain for system (2.1) is Ω, the proof of Lemma 2 implies Ω attracts the trajectories of (2.1) starting at any x0∈R2+, so in principle there exist T>0 with Ω⊂W(T).
The set W(T) can be characterized using a level-set approach based on the computed value function v by avoiding any controllability assumption for (2.1). We formulate a minimization problem (4.3) for a value function w, which is the unique continuous viscosity solution of a Hamilton-Jacobi-Bellman equation [33,Definition 2 and Theorem 2].
To impose a restriction W(T)⊆Ω into the variational formulation, we introduce a penalization term GΩ(x), which is a Lipschitz-continuous function which satisfies the condition for sub-zero-level set, GΩ(x)≤0 if and only if x∈Ω.
To compute the minimal entry time function, we consider the solution w of the minimization problem
Note that w is defined over R2, but the penalization term in (4.3) makes the value function w positive if the trajectory leaves the domain Ω. The backwards reachable set W(T) for (2.1) is thus defined as the sub-zero-level set of the function w, W(T)={x∈R2|w(T,x)≤0}, and (4.3) implies W(T)⊆Ω.
Following reference [33,Lemma 1], the value function w satisfies the following dynamic programming principle
with ∇w=(∂x1w,∂x2w), and Hamiltonian H provided by (3.12).
Using w, we define the minimal entry time function (4.1) TV(ˉI,ˉu)(x) for V(ˉI,ˉu) for a trajectory with initial condition x as
TV(ˉI,ˉu)(x)=inf{t≥0|x∈W(t)}=inf{t≥0|w(t,x)≤0}.
As there is no controllability assumption for (2.1), TV(ˉI,ˉu) need not be continuous over Ω. In fact, the proof of part (ii) of Proposition 2 reveals that the minimal entry time function exhibits a discontinuity across the boundary of the viability kernel V(ˉI,ˉu) traced by the solution curve Z defined in Lemma 3. Observe that even though the biologically relevant domain for (2.1) is just Ω, TV(ˉI,ˉu)(x) may take finite values for points x∉Ω, while TV(ˉI,ˉu)(x)=+∞ for x:x1,x2<0.
For the purpose of our study we are interested in minimal entry times not exceeding a given time horizon T. As Ω is positively invariant under f, we employ the penalization term
GΩ(x)={−1,x∈Ω,1,x∉Ω.
To achieve higher accuracy of approximation for w(t,x),t∈[0,T] close to the boundary ∂Ω we solve numerically (4.5) on a uniform stencil for a domain which contains Ω in its interior using a second-order Runge-Kutta scheme for the time integration. We find an approximation of the minimal entry time function on Ω by using the obtained solution values for w(t,x),x∈Ω, as well as the optimal control using the reconstruction algorithm given in references [31,32].
5.
Results and discussion
Mathematical analysis of models for vector-borne diseases tends to concern the asymptotic rather than the transient behavior of their solutions using the basic reproduction number R0 as a criterion for the stability of the disease-free equilibrium [34,35,36,37]. Of interest are the parameter values that keep R0 below unity. Applications of optimal control theory often focus on optimal allocation of resources (by minimizing cost functionals of different form) without addressing future transient dynamic behavior [38].
In this work we study the latter question by considering a control problem with restricted state space, defined by a cap on the size of the infected host compartment, and address two major questions. In Question Q.1 we seek the viability kernel V for the model (2.1), the subset of the state space Ω that comprises those initial data such that a viable control u(t) exists to maintain the size of infected host compartment x1(t) below the infection cap ˉI for all future times. Then, we address a reachability problem formulated as Question Q.2. If the interventions start from an initial condition x0∉V which is outside the viability kernel, the objective stated in Question Q.1 cannot be met, so instead we are interested in finding the optimal control strategy u(t) which reduces x1(t) below ˉI in the shortest time. The motivation behind Question Q.2 relates to the fact that control measures studied here are restricted in duration due to technological and design limitations leading to a loss of product's repellent property.
Analysis of viability and reachability allows decision makers to assess the effect of this control intervention on future transient behavior given the epidemic situation at the start. This framework gives an opportunity to analyze the dynamic behavior of the controlled model on its entire domain of definition, or large subsets thereof, by describing existence of viable controls and of sets reachable in finite time. In particular, it is possible to estimate whether under the constraints of cost Cmax (which determines the population coverage ˉu) and duration of repellent action T, the objective of reducing the size of the infected host compartment below the infection cap ˉI can be met.
The reachability analysis could serve as a predictive indicator for the performance of the intervention with parameters ˉu,ˉI,T by providing analysis of the model's trajectories. If a trajectory which reaches the target (viability kernel) within the time interval (0,T) exists, the campaign is considered effective. Else, the intervention strategy is to be considered insufficient and may need to be supplemented by additional measures (use of repellents with higher efficacy, use of LLINs, indoor residual spraying, vaccinations, preventive treatment, etc.).
We use parameter values for a malaria model fitted for Botswana and Zimbabwe from reference [19] (listed in Table 1) as a basis for the numerical simulations to exemplify this method. Viability kernels and minimal entry time functions are computed and compared across different values of ˉu.
Table 1.
Model parameters based on reference [19] used in the numerical simulation for Botswana and Zimbabwe. The values in parentheses refer to Zimbabwe.
The main differences between the parameters is the mosquito biting rate, am=0.082 for Botswana and am=0.241 for Zimbabwe, and the expected life-time of a mosquito 1/μ, which is three times higher in Botswana. According to reference [19] and therein cited references, the parameter μ reflects a difference in overall coverage of indoor residual spraying in the two countries. This intervention influences the vector's demography and ecology by direct insecticidal or repellent action, but different spraying solutions are used in homes built from traditional materials (wood, clay or mud bricks) and in Western-style housing [39]. While it has suppressed the transmission of malaria in the past, societal refusal to indoor spraying due to pungency, home wall staining, bug infestation, etc. is on the rise [40], and the positive trends in disease control have been reversed.
The results from Proposition 1 enable us to compute the threshold for population coverage minˉu such that for a given infection cap ˉI the viability kernel V(ˉI,ˉu) is not trivial:
minˉu=1k−βγˉI+√(βγˉI)2+4αβγμν(1−ˉI)2αβγν(1−ˉI)k.
(5.1)
If minˉu≤0, then the viability kernel V(ˉI,ˉu) has a positive Lebesgue measure in R2 for all 0≤ˉu≤1.
Figure 1 plots the trade-off relationship (5.1) between ˉI,minˉu for both countries for two values of repellent efficacy k. It shows the minimal coverage ˉu required to produce a viability kernel of positive Lebesgue measure for the given infection cap ˉI. An immediate consequence is that in the case of Botswana, for ˉI≥0.01, any extent of the control measures will suffice to produce a non-trivial viability kernel. In contrast, more control efforts must be employed in the case of Zimbabwe, where at least 20% population coverage is required (minˉu>0.2) to produce a non-trivial viability kernel. Of course, we must look at the area of the viability kernel to evaluate better the potential for keeping the epidemic peak below ˉI with the repellent-based strategy under consideration.
Figure 1.
Trade-off relationship between ˉI and minˉu to keep the viability kernel V(ˉI,ˉu) with positive Lebesgue measure. Range of ˉI:(10−3,10−1) for two values of the repellent efficacy k. Parameters used for a) Botswana, b) Zimbabwe.
The infection cap is ˉI=0.1 and repellent efficacy k=0.6. The epidemiological parameters for Botswana indicate that the viability kernels are not trivial for all 0≤ˉu≤1. Figure 2a) displays the area of the viability kernel for a range of values of ˉu. There is a positive correlation between ˉu and the area of V(ˉI,ˉu). For the given epidemiological parameters in Zimbabwe, the situation is different: for ˉI=0.1 the viability kernel is trivial if ˉu<0.2152; in other words, under this assumption the model predicts it is not possible to maintain the size of infected host compartment below ˉI for any initial data in Ω if the population coverage is less than 21.5%. The area of the viability kernel for a range of values of ˉu≥0.215 is plotted in Figure 2b).
Figure 2.
Area of the viability kernel V(ˉI,ˉu) as function of the campaign's extent ˉu. Parameters for a) Botswana; b) Zimbabwe.
Examples of viability kernels' shape for Botswana are shown in Figure 3. The viability kernels for Zimbabwe have a similar shape as those for Botswana, displayed in the panels of Figure 3, and are not shown.
Figure 3.
Numerical approximation of the viability kernel V(ˉI,ˉu) for the epidemiological model. Parameters for Botswana with maximum coverage: a) ˉu=0.6, b) ˉu=0.7, c) ˉu=0.8, d) ˉu=0.9.
An example for a reconstructed optimal trajectory inside Ω is given in Figure 4a), and the control effort – in Figure 4b) – it is computed using the algorithm from reference [31]. Note that for the same initial data, without intervention, the size of infected host compartment x1 exceeds the cap ˉI (the trajectory follows the purple curve in Figure 4a).
Figure 4.
a) An example of a reconstructed optimal trajectory (red) maintained inside the viability kernel versus the trajectory with no control u(t)≡0 (purple). b) Plot of the corresponding control function. Parameters for Botswana with ˉu=0.6.
The numerical approximations for the minimal entry time functions TV(ˉI,ˉu) are shown in Figure 5 for Botswana and Figure 6 for Zimbabwe. In the simulations we use an infection cap of 10% of the population (ˉI=0.1) and a time horizon of three months (T=100 days). The results show that with these constraints, under the parameter values for Botswana, an outbreak would be successfully brought under the infection cap within the given time horizon, unless the proportion of infected mosquitos is very high. In fact, for ˉu=0.6, the set of initial data x0 such that TV(x0)<100 days (those such that the size of the infected host compartment can be reduced to less than 0.1 within 100 days) is contained within the rectangle [0,1]×[0,0.25] and for ˉu=0.9, it coincides almost fully with the rectangle [0,1]×[0,0.5]. That means that increasing the coverage from 60% to 90% of the population approximately doubles the area of the set {x0|TV(x0)<100 days}. However, at very high levels of infected mosquitos at the start of the intervention (x2(0)>0.5) the intervention cannot be considered effective as for all different extents of coverage ˉu∈[0.6,0.9] the minimal time needed to reduce the outbreak size below the prescribed cap exceeds 100 days.
Figure 5.
Numerical approximation of the minimum entry time function TV(ˉI,ˉu) (plot of isolines indicating days). Parameters for Botswana with maximum coverage: a) ˉu=0.6, b) ˉu=0.7, c) ˉu=0.8, d) ˉu=0.9.
Figure 6.
Numerical approximation of the minimum entry time function TV(ˉI,ˉu) (plot of isolines indicating days). Parameters for Zimbabwe with maximum coverage: a) ˉu=0.6, b) ˉu=0.7, c) ˉu=0.8, d) ˉu=0.9.
For Zimbabwe, the minimal entry time functions show that for the same maximum population coverage with repellent ˉu less time is required to bring the outbreak under the chosen infection cap ˉI. The isolines in Figure 6 follow a radial pattern rather than parallel shifts like those for Botswana. Even at ˉu=0.6 for the entire set of initial conditions x0∈[0,1]×[0,0.5] the minimal entry time to the viability kernel is less than 90 days. Reconstructed optimal trajectories for the reachability problem in Question Q.2 for an initial condition x0=(0.3,0.2) are plotted in Figure 7.
Figure 7.
Reconstructed optimal trajectories for the minimal time needed to bring the size of the infected compartment I below the cap ˉI=0.1 (dashed line in the left panels) if the intervention starts at initial data x0=(0.3,0.2) for a) Botswana the minimal entry time T(x0)=86.7 days, b) Zimbabwe the minimal entry time T(x0)=63.4 days. Parameter of maximum coverage ˉu=0.6.
It may seem paradoxical that for the model with parameters for Zimbabwe the minimal entry time to the respective viability kernel is shorter than for Botswana; in other words, a scenario with a higher basic reproduction number R0 appears more elastic in its response to the campaign of repellent-based interventions modeled by (2.1). That elasticity could be explained with the difference in the vector's ecology: the model is parameterized with a threefold higher mortality rate for the mosquitos in Zimbabwe (μ=110) relative to Botswana (μ=130), despite the fact that the pathogen transmission rate from vector to host α, and R0 for a baseline scenario of no control (u(t)=0) are higher for Zimbabwe [19]. This simple example shows how transient dynamical properties of the controlled system (2.1) in the case of endemicity stay decoupled from the value of a traditional epidemiological metric R0.
These simulations agree with {entomological} observations of the importance of interventions which target the vector's demography such as indoor residual spraying, LLINs, etc, for suppressing pathogen transmission [41]. Different societal behavior and inconsistent following of measures such as indoor spraying [19] can potentially have an impact on the performance of interventions such as those considered here and their ability to suppress sporadic outbreaks in the shortest time. The extent of compliance with a measure that is considered primary for malaria control by the WHO may influence the performance of alternative interventions reliant on {repellent-based personal protection}. This result stresses the importance for a multi-modal approach in controlling vector-borne disease outbreaks.
Our model has several limitations: first, it assumes that the host population is homogeneous, and does not consider age structure or differentiation in terms of disease status (such as asymptomatic, mild, severe and in need of treatment). Second, the host and vector populations are taken constant in time, ignoring effects of seasonal changes on the transmission dynamics. Third, it assumes that all hosts receive the same level of protection by the control effort, but population heterogeneity due to variability in repellent action may exist. Finally, (2.1) does not model immunity in the population. These issues can be addressed by increasing model complexity, including seasonal variations in the mosquito population, adding more compartments for the host population, etc. The state constraint (infection cap) can also be redefined to the respective class of infected (e.g., those in need of treatment). The proposed analytical framework can be adapted for extensions of the model (2.1), such as a time-delay system, a combination of measures (use of insecticides or vaccinations), or a system with an infected and infectious vector compartments [42].
6.
Conclusion
We have used optimal control theory to solve problems of existence of viable controls and of reachability for a simple model of a vector-borne disease. Available mathematical tools exist that allow decision and policy makers to assess effects of the control intervention on transient dynamics of the model in finite times, rather than just to determine asymptotic properties of equilibria. This approach reveals that, sometimes, depending on the epidemiological parameters and the state of the epidemic (determined by the size of infected host and vector compartments), even extending control efforts to the maximum may not suffice to meet policy objectives such as reduction of the size of the infected compartment below a given level in a fixed time span. Hence, existence of controls that satisfy the constraints of the intervention can be interpreted as an efficiency metric, which suggest whether the current intervention is sufficient or a combination of additional intervention modes may be required. Of course, to be able to make reliable predictions for the performance of a given control intervention, the model should use parameters rightful for the provided epidemiological and/or entomological data.
The presented model is based on assumptions of population homogeneity, simple disease dynamics and linear cost function for the control, and bringing the model closer to real-world scenarios will undoubtedly increase its complexity. Adding additional state variables means adding an extra dimension to the Hamilton-Jacobi-Bellman equation, and increases the computational complexity for the numerical approximation of the value function and the minimal entry time function. This obstacle should be addressed by development of appropriate, more efficient numerical methods for solving the associated optimal control problem.
Acknowledgments
The author would like to thank Bob W. Kooi for helpful discussion during the preparation of the manuscript. This work is supported by the Bulgarian National Science Fund (FNI) within the National Scientific Program Petar Beron i NIE of the Bulgarian Ministry of Education [contract KP-06-DB-5]
Conflict of interest
The author declares there is no conflict of interest.
Supplementary Material
Proof of Lemma 2. For part (i), consider the Lyapunov candidate function on Ω:
L=β(1−kˉu)γy1+y2.
Note that on Ω∈R2+, L≥0 with equality attained only at the disease-free equilibrium at the origin O.
Hence L is positive definite, |L|→+∞ on R2+ and dL/dt is negative definite on R2+∖O. Then Lyapunov's stability theorem [43,Chapter 5.26] implies that the disease-free equilibrium O is globally asymptotically stable.
For part (ii), the global asymptotic stability of the endemic equilibrium (3.5) for the 2-dimensional system (2.1) is shown using the Lyapunov candidate function:
As y1,y2>0, equality dL/dt=0 can be achieved only at E∗. Thus L is positive definite and dL/dt is negative definite on Ω∖O. Lyapunov's stability theorem implies that the endemic equilibrium E∗ is globally asymptotically stable.
Proof of Proposition 1. The proof of case (i) is based on the local asymptotic stability of the disease-free or the endemic equilibrium of the system (2.1) with constant controls. In particular, we distinguish between 2 cases: first, if Icrit≤0, then O is globally asymptotically stable for (2.1) with u(t)≡ˉu (see Lemma 2). This means that trajectories starting from any neighbourhood of O that is sufficiently small and contained inside A(ˉI) will converge to the equilibrium, maintaining the constraint on x1(t)<ˉI for all t>0.
Second, if Icrit>0, then the endemic equilibrium E∗ is globally asymptotically stable for (2.1) with u(t)≡ˉu, and E∗∈A(ˉI) (see Lemma 2). To show that intV has a positive Lebesgue measure in R2, we consider the lens-shaped set D0 bounded by the x1- and x2-nullcline inside A(ˉI), and show it is a viability domain for (2.1) (see Figure S1). The x1-nullcline is given by
N1={(x1,x2)|0≤x1≤Icrit,x2=γx1α(1−kˉu)ν(1−x1)}
(6.1)
with the outward-pointing normal
nN1=(1,−γα(1−kˉu)ν(1−x1)2)T.
For x∈N1, it holds f2(x,ˉu)=x1(αβν(1−kˉu)2−γμ)−x21(αβν(1−kˉu)2+γβ(1−kˉu))α(1−kˉu)ν(1−x1)≥0 with equality at O and E∗, so ⟨f(x,ˉu),nN1⟩=−γf2(x,ˉu)α(1−kˉu)ν(1−x1)2≤0, and the curve (6.1) is impermeable from intD0 for the flow f(x,ˉu). The x2-nullcline is given by
N2={(x1,x2)|0≤x1≤Icrit,x2=β(1−kˉu)x1β(1−kˉu)x1+μ}
(6.2)
with the outward-pointing normal
nN2=(−1,β(1−kˉu)μ(β(1−kˉu)x1+μ)2)T.
For x∈N2, it holds f1(x,ˉu)=x1(αβν(1−kˉu)2−γμ)−x21(αβν(1−kˉu)2+γβ(1−kˉu))β(1−kˉu)x1+μ≥0 again with equality at O and E∗, so ⟨f(x,ˉu),nN2⟩=−f1(x,ˉu)≤0 and the curve (6.2) is impermeable from intD0 for the flow f(x,ˉu). We conclude that this lens-shaped set D0 is forward invariant under f(x,ˉu) and D0⊂A(ˉI) is a viability domain, completing the proof of case (i).
The proof of (ii) uses the componentwise inequality f(x,u)≥f(x,ˉu),∀x∈Ω to invoke the comparison theorem [20] and obtain
xu(t;x0)≥xˉu(t;x0),∀t>0
(6.3)
so xˉu(t;x0) is a subsolution for (2.1) for all x0. Lemma 2 establishes that for any initial condition x0∈Ω∖O, this subsolution converges to E∗∈Ω∖A(ˉI). In other words, there exists τ>0 such that for the subsolution xˉu(t;x0), xˉu1(t)>ˉI for all t>τ. The comparison (6.3) implies that for the any feasible trajectory xu(t;x0) of the control system (2.1), xu1(t)≥xˉu1(t)>ˉI for all t>τ. Thus, the only forward invariant set inside V(ˉI,ˉu) is the disease-free equilibrium O.
Proof of Lemma 3. Denote for the sake of shortness ˜α=αν(1−kˉu),˜β=β(1−kˉu), and ˜f1(z,s)=f1(z,s,ˉu),˜f2(z,s)=f2(z,s,ˉu), and H(s,z)=˜f1(z,s)˜f2(z,s) the right-hand side of (3.6).
Figure 1.
Phase portrait of the model with nullclines f1 = f2 = 0.
so long as ˜α˜β−γμ≤0 (when Icrit≤0) or when ˉI>Icrit,˜α˜β−γμ>0. Therefore,
ddsz(ˉv)=0.
(6.5)
We have
˜f1(z,s)>˜f1(˜z,˜s),˜f2(z,s)<˜f2(˜z,˜s) if s>˜s,z<˜z,
(6.6)
and in particular, ˜f1(z,s)>˜f1(ˉI,ˉv) and ˜f2(z,s)<˜f2(ˉI,ˉv) if s>ˉv,z<ˉI. Also we have max˜f1(z,s)<+∞,min˜f2(z,s)>−∞ on Ω.
This implies that the denominator of H is negative and bounded away from 0 on [ˉv,1]×[0,ˉI] due to (6.4). Consequently, being a rational function, H is continuous in s and uniformly Lipschitz in z on [ˉv,1]×[0,ˉI]. By the Picard-Lindelöf theorem, there exists ε>0 such that (3.6) has a unique C1-solution z(s) for s∈[ˉv,ˉv+ε). We show now that this solution z(s) exists on the entire interval [ˉv,+∞).
We verify that z(s) is monotone decreasing on [ˉv,ˉv+ε) based on (6.5). Since z is C1, its Taylor expansion around ˉI=z(ˉv) reads
Thus, there exists ε>0 such that for values ˉv<s<ˉv+ε, ˜f1(z(s),s)>0, while ˜f2(z(s),s)<0 due to (6.4). Hence, the solution z is monotone decreasing on [ˉv,ˉv+ε), and due to the monotonicity of ˜f1,˜f2 provided by (6.6), H<0 strictly on (ˉv,+∞)×[0,ˉI). Because the solution z(s),s>ˉv is bounded by z(ˉv)=ˉI irrespectively of ε, it can be continued on the whole interval [ˉv,+∞, and remains monotone decreasing because dz/ds<0.
Note that it might happen that z(v∗)=0 for some ˉv<v∗≤1. Then we restrict the solution curve Z to the domain [ˉv,v∗]. This completes the proof.
Proof of Proposition 2. The proof follows the ideas from reference [17]. To show that the proposed sets are viability kernels, we have to verify their forward invariance under f(x,u) (that is, that they are viability domains for f) and their maximality.
Case (i). Consider the segment s={ˉI}×[0,1], which forms the eastern boundary of A(ˉI) in the (x1,x2)-state space and the outward-pointing normal to s, ns=(1,0)T. Then ⟨f(ˉI,x2,ˉu),ns⟩=α(1−kˉu)νx2(1−ˉI)−γˉI≤(1−kˉu)αν(1−ˉI)−γˉI<0. This means there exists a control function u∈U such that the entire set A(ˉI) is forward invariant under (2.1), and therefore, V(ˉI,ˉu)=A(ˉI).
Case (ii). Let D={[0,ˉI]×[0,ˉv]}∪{(x1,x2)|ˉv≤x2≤min{v∗,1},0≤x1≤z(x2)}. Recall ˉv from Lemma 3. Observe that on the segment s2={ˉI}×(ˉv,1], the inner product of the velocity field f and the outward-pointing normal n2 to s2, ⟨f(ˉI,x2,u),n2⟩=α(1−ku)νx2(1−ˉI)−γˉI>(1−ku1−kˉu−1)γˉI≥0. Hence, by continuity of f, a neighbourhood of s2 in A(ˉI) is not contained inside V(ˉI,ˉu). On the other hand, on the segment s1={ˉI}×[0,ˉv] the inner product of the velocity field f and the outward-pointing normal n1 to s1, ⟨f(ˉI,x2,ˉu),n1⟩≤0. Finally, the outward-pointing normal to Z is ˜n=(1,−z′(x))T. Then ⟨f(z(x2),x2,ˉu),˜n)=0. Hence, by choosing u=ˉu, Z is impermeable to the flow of f(x,ˉu). Thus, there exists u such that the interior intD is forward invariant under f(x,u).
Finally to conclude that D is forward invariant, we show that the curve Z∈D, itself being a feasible trajectory for (2.1) with u=ˉu. Indeed, the inequality x02>ˉv,x01<ˉI holds for any initial data x0=(x01,x02)∈Z. Therefore, ˜f2(x01,x02)<˜f2(ˉI,ˉv)<0 by (6.4), and since ddtx2(x0)<0, it follows x2(t)<x02,t>0.
Let τB(x0) be the minimal entry time function (4.1) to the target set B={(x1,x2)|x1>ˉI∨x2<ˉv} for the control u(t)=ˉu, or
τB(x0)=inft>0{t|xˉu(t;x0)∈B}.
Since B contains the globally asymptotically stable endemic equilibrium E∗ (3.5), τ(x0)<+∞ for all x0∈Z.
We choose any initial condition x0∈Z. Then the trajectory of (2.1) for u=ˉu satisfies x2(t)<ˉv for t>τ(x0). Thus, {x2(t)|t∈[0,τ(x0)]}⊂[ˉv,min{v∗,1}] and x2(t) takes values inside the domain of the function z which solves the problem (6.4). On t∈[0,τ(x0)] the difference between x1(t) and z(x2(t) remains constant in t because
ddt(x1(t)−z(x2(t))=f1(x,ˉu)−f2(x,ˉu)dzdx2=0,
Due to the initial condition x0∈Z, x1(0)−z(x2(0))=0, so the above implies x1(t)−z(x2(t))=0,t∈(0,τ(x0)) implying that the curve Z is part of a feasible trajectory for (2.1).
As it holds by construction, either x1(τ(x0))=ˉI or x2(τ(x0))=ˉv, by the inverse function theorem for z we obtain that xˉux0(τ(x0))=(ˉI,ˉv). Since x0∈Z was chosen arbitrary, the entire curve Z as defined by the Lemma consists of a trajectory for (2.1). We have demonstrated that the set D as defined in (3.6) is closed, forward invariant under f(x,u) and it is a viability domain for f(x,u).
It remains to show that D is the maximal viability domain for f(x,u). Consider an initial condition y0∈A(ˉI)∖D for f and {claim} the trajectory xˉu(t,y0) leaves A(ˉI) in finite time. It holds y01<ˉI, but y02>z−1(y01) due to the definition of D. Denote ˜y0=(y01,z−1(y01)), meaning ˜y0≤y0 componentwise. Since the map f is quasimonotone, we can use the comparison principle [24,Chapter 3] to obtain the componentwise inequalities
xu(t;y0)≥xˉu(t;y0)≥xˉu(t;˜y0),∀t>0.
Therefore, the first element in the difference vector Δ(t)=xˉu(t;y0)−xˉu(t;˜y0), which we denote by Δ1(t) satisfies Δ1∈C1(0,+∞),Δ1(t)≥0.
Denote τ0=τ(˜y0), which means ˜y1(τ0)=[xˉu(τ0;˜y0)]1=ˉI. Assume y1(τ0)=[xˉu(τ0;y0)]1=ˉI, which translates to Δ1(τ0)=0, and Δ1 having a local minimum at t=τ0. Hence,
ddtΔ1(τ0)=0⇒f1(xˉu(τ0;y0),ˉu)=f1(xˉu(τ0;˜y0),ˉu).
(6.7)
Plugging in the equality y1(τ0)=˜y1(τ0)=ˉI into (6.7), we see that
˜α(1−ˉI)(y2(τ0)−˜y2(τ0))=0⇒y2(τ0)=˜y2(τ0),
and obtain xˉu(τ0;y0)=xˉu(τ0;˜y0). With y≠˜y, this equality is a contradiction to the uniqueness of the solution trajectory to the autonomous system ddty=f(y,ˉu). Therefore, y1(τ0)>˜y1(τ0)=ˉI, showing that y0∉V(ˉI,ˉu). This argument shows D is maximal, and we conclude V(ˉI,ˉu)=D.
References
[1]
Ananth DA, Mahalakshmi V, Sivasudha T, et al. (2021) Identification and quantification of polyphenols from Cassia auriculata L. leaf, flower and flower bud using UPLC-QqQ-MS/MS. Isr J Plant Sci 68: 133–141. https://doi.org/10.1163/22238980-bja10027 doi: 10.1163/22238980-bja10027
[2]
Tietel Z, Ananth DA, Sivasudha T, et al. (2021) Metabolomics of Cassia auriculata plant parts (leaf, flower, bud) and their antidiabetic medicinal potentials. OMICS: J Integr Biol 25: 294–301. https://doi.org/10.1089/omi.2021.0010 doi: 10.1089/omi.2021.0010
[3]
Anitha R, Subashini R, Kumar PS (2020) In silico and in vitro approaches to evaluate the bioactivity of Cassia auriculata L extracts. IET Nanobiotechnol 14: 210–216. https://doi.org/10.1049/iet-nbt.2019.0364 doi: 10.1049/iet-nbt.2019.0364
[4]
Girme A, Saste G, Ghule C, et al. (2019) Phytoanalytical profiling of Cassia auriculata by LC-PDA-ESI-MS/MS and HPTLC supporting its metabolic claims. Planta Med 85: 1439. https://doi.org/10.1055/s-0039-3399767 doi: 10.1055/s-0039-3399767
[5]
Aye MM, Aung HT, Sein MM, et al. (2019) A review on the phytochemistry, medicinal properties and pharmacological activities of 15 selected Myanmar medicinal plants. Molecules 24: 293. https://doi.org/10.3390/molecules24020293 doi: 10.3390/molecules24020293
[6]
Anandan A, Eswaran R, Doss A, et al. (2011) Chemical compounds investigation of Cassia auriculata leaves–a potential folklore medicinal plant. Bull Environ, Pharm Life Sci 1: 20–23.
[7]
Meena V, Baruah H, Parveen R (2019) Cassia auriculata: A healing herb for all remedy. J Pharm Phytochem 8: 4093–4097.
[8]
Nille GC, Reddy KR (2015) A phytopharmacological review of plant–Cassia auriculata. Int J Pharm Biol Arch 6: 1–9.
[9]
Khurm M, Wang X, Zhang H, et al. (2020) The genus Cassia L.: Ethnopharmacological and phytochemical overview. Phytother Res 35: 2336–2385. https://doi.org/10.1002/ptr.6954 doi: 10.1002/ptr.6954
[10]
Shafeeq RS, Shekshavali T, Ahamed SSS (2018) A Review on Cassia auriculata. Res J Pharmacol Pharmacodyn 10: 141–145. https://doi.org/10.5958/2321-5836.2018.00026.5 doi: 10.5958/2321-5836.2018.00026.5
[11]
Wasana KGP, Attanayake AP, Arawwawala LDAM (2022) Ethnobotanical survey on medicinal plants used for the treatment of diabetes mellitus by Ayurveda and traditional medicine practitioners in Galle district of Sri Lanka. Eur J Integr Med 55: 102177. https://doi.org/10.1016/j.eujim.2022.102177 doi: 10.1016/j.eujim.2022.102177
[12]
Latha M, Pari L (2003) Antihyperglycaemic effect of Cassia auriculata in experimental diabetes and its effects on key metabolic enzymes involved in carbohydrate metabolism. Clin Exp Pharmacol Physiol 30: 38–43. https://doi.org/10.1046/j.1440-1681.2003.03785.x doi: 10.1046/j.1440-1681.2003.03785.x
[13]
Nambirajan G, Karunanidhi K, Ganesan A, et al. (2018) Evaluation of antidiabetic activity of bud and flower of Avaram Senna (Cassia auriculata L.) In high fat diet and streptozotocin induced diabetic rats. Biomed Pharmacother 108: 1495–1506. https://doi.org/10.1016/j.biopha.2018.10.007 doi: 10.1016/j.biopha.2018.10.007
[14]
Sathasivampillai SV, Rajamanoharan PR, Munday M, et al. (2017) Plants used to treat diabetes in Sri Lankan Siddha Medicine–An ethnopharmacological review of historical and modern sources. J Ethnopharmacol 198: 531–599. https://doi.org/10.1016/j.jep.2016.07.053 doi: 10.1016/j.jep.2016.07.053
[15]
Rajagopal SK, Manickam P, Periyasamy V, et al. (2003) Activity of Cassia auriculata leaf extract in rats with alcoholic liver injury. J Nutr Biochem 14: 452–458. https://doi.org/10.1016/S0955-2863(03)00053-6 doi: 10.1016/S0955-2863(03)00053-6
[16]
Nakamura S, Xu F, Ninomiya K, et al. (2014) Chemical structures and hepatoprotective effects of constituents from Cassia auriculata leaves. Chem Pharm Bull 62: 1026–1031. https://doi.org/10.1248/cpb.c14-00420 doi: 10.1248/cpb.c14-00420
[17]
Sharmila G, Nikitha V, Ilaiyarasi S, et al. (2016) Ultrasound assisted extraction of total phenolics from Cassia auriculata leaves and evaluation of its antioxidant activities. Ind Crops Prod 84: 13–21. https://doi.org/10.1016/j.indcrop.2016.01.010 doi: 10.1016/j.indcrop.2016.01.010
[18]
Gunathilake K, Ranaweera K, Rupasinghe H (2018) Analysis of rutin, β‐carotene, and lutein content and evaluation of antioxidant activities of six edible leaves on free radicals and reactive oxygen species. J Food Biochem 42: e12579. https://doi.org/10.1111/jfbc.12579 doi: 10.1111/jfbc.12579
[19]
Prasathkumar M, Raja K, Vasanth K, et al. (2021) Phytochemical screening and in vitro antibacterial, antioxidant, anti-inflammatory, anti-diabetic, and wound healing attributes of Senna auriculata (L.) Roxb. leaves. Arab J Chem 14: 103345. https://doi.org/10.1016/j.arabjc.2021.103345 doi: 10.1016/j.arabjc.2021.103345
[20]
Bandawane D, Beautikumari S, Gate S, et al. (2014) Evaluation of anti-arthritic activity of ethyl acetate fraction of Cassia auriculata Linn. leaves. Biomed Aging Pathol 4: 105–115. https://doi.org/10.1016/j.biomag.2013.10.009 doi: 10.1016/j.biomag.2013.10.009
[21]
Sutar S, Korpale S, Nadaf S, et al. (2023) Anti-arthritic activity of Senna auriculata leaves extract on formaldehyde-induced arthritic rats. J Res Pharm 27: 1402. https://doi.org/10.29228/jrp.427 doi: 10.29228/jrp.427
[22]
Gupta S, Sharma SB, Bansal SK, et al. (2009) Antihyperglycemic and hypolipidemic activity of aqueous extract of Cassia auriculata L. leaves in experimental diabetes. J Ethnopharmacol 123: 499–503. https://doi.org/10.1016/j.jep.2009.02.019 doi: 10.1016/j.jep.2009.02.019
[23]
Shanmugam H, Venkatesan RS (2022) Determination of antihyperglycemic activity of ethanolic crude leaf extract of Cassia auriculata in the streptozocin induced male wistar albino rats. Int J Health Sci 6: 5617–5630. https://doi.org/10.53730/ijhs.v6nS3.7190 doi: 10.53730/ijhs.v6nS3.7190
[24]
Khader SZA, Ahmed SSZ, Balasubramanian SK, et al. (2017) Modulatory effect of dianthrone rich alcoholic flower extract of Cassia auriculata L. on experimental diabetes. Integr Med Res 6: 131–140. https://doi.org/10.1016/j.imr.2017.01.007 doi: 10.1016/j.imr.2017.01.007
[25]
Fauzi FM, John CM, Karunanidhi A, et al. (2017) Understanding the mode-of-action of Cassia auriculata via in silico and in vivo studies towards validating it as a long term therapy for type Ⅱ diabetes. J Ethnopharmacol 197: 61–72. https://doi.org/10.1016/j.jep.2016.07.058 doi: 10.1016/j.jep.2016.07.058
[26]
Pari L, Latha M (2002) Effect of Cassia auriculata flowers on blood sugar levels, serum and tissue lipids in streptozotocin diabetic rats. Singapore Med J 43: 617–621.
[27]
Abesundara KJ, Matsui T, Matsumoto K (2004) α-Glucosidase inhibitory activity of some Sri Lanka plant extracts, one of which, Cassia auriculata, exerts a strong antihyperglycemic effect in rats comparable to the therapeutic drug acarbose. J Agric Food Chem 52: 2541–2545. https://doi.org/10.1021/jf035330s doi: 10.1021/jf035330s
[28]
Grace B, Viswanathan M, Wilson DD (2022) A new silver nano-formulation of Cassia auriculata flower extract and its anti-diabetic effects. Recent Pat Nanotechnol 16: 160–169. https://doi.org/10.2174/1872210515666210329160523 doi: 10.2174/1872210515666210329160523
[29]
Vijayakumar R, Nachiappan V (2017) Cassia auriculata flower extract attenuates hyperlipidemia in male Wistar rats by regulating the hepatic cholesterol metabolism. Biomed Pharmacother 95: 394–401. https://doi.org/10.1016/j.biopha.2017.08.075 doi: 10.1016/j.biopha.2017.08.075
[30]
Vijayaraj P, Muthukumar K, Sabarirajan J, et al. (2013) Antihyperlipidemic activity of Cassia auriculata flowers in triton WR 1339 induced hyperlipidemic rats. Exp Toxicol Pathol 65: 135–141. https://doi.org/10.1016/j.etp.2011.07.001 doi: 10.1016/j.etp.2011.07.001
[31]
Lingaiah, Mamidala E, Rao PN (2017) Modulatory effect of Cassia auriculata plant extraction on glucose metabolism in alloxan induced diabetic wistar rats. Amer J Sci Med Res 3: 8–11.
[32]
Murugan P, Sakthivel V (2021) Effect of cassia auriculata on lipid profiles in streptozotocin–nicotinamide induced type 2 diabetes mellitus. J Popul Ther Clin Pharmacol 28: 73–79. https://doi.org/10.53555/jptcp.v28i01.2440 doi: 10.53555/jptcp.v28i01.2440
[33]
Kumaran A, Karunakaran RJ (2007) Antioxidant activity of Cassia auriculata flowers. Fitoterapia 78: 46–47. https://doi.org/10.1016/j.fitote.2006.09.031 doi: 10.1016/j.fitote.2006.09.031
[34]
Latha M, Pari L (2003) Preventive effects of Cassia auriculata L. flowers on brain lipid peroxidation in rats treated with streptozotocin. Mol Cell Biochem 243: 23–28. https://doi.org/10.1023/A:1021697311150 doi: 10.1023/A:1021697311150
[35]
Kolar FR, Gogi CL, Khudavand MM, et al. (2018) Phytochemical and antioxidant properties of some Cassia species. Nat Prod Res 32: 1324–1328. https://doi.org/10.1080/14786419.2017.1342085 doi: 10.1080/14786419.2017.1342085
[36]
Kumar JSP, Tharaheswari M, Subhashree S, et al. (2014) Cassia auriculata flower extract articulate its antidiabetic effects by regulating antioxidant levels in plasma, liver and pancreas in T2DM rats. AJPCT 2: 705–722.
[37]
John CM, Sandrasaigaran P, Tong CK, et al. (2011) Immunomodulatory activity of polyphenols derived from Cassia auriculata flowers in aged rats. Cell Immunol 271: 474–479. https://doi.org/10.1016/j.cellimm.2011.08.017 doi: 10.1016/j.cellimm.2011.08.017
[38]
Jancy VJJ, Kalaichelvan V, Balakrishnan N (2020) Phytochemical analysis and anti-oxidant activity of various extracts of plant Cassia auriculata. Res J Pharm Technol 13: 6150–6155. https://doi.org/10.5958/0974-360X.2020.01073.2 doi: 10.5958/0974-360X.2020.01073.2
[39]
Juan-Badaturuge M, Habtemariam S, Thomas MJ (2011) Antioxidant compounds from a South Asian beverage and medicinal plant, Cassia auriculata. Food Chem 125: 221–225. https://doi.org/10.1016/j.foodchem.2010.08.065 doi: 10.1016/j.foodchem.2010.08.065
[40]
Habtemariam S (2013) Antihyperlipidemic components of Cassia auriculata aerial parts: Identification through in vitro studies. Phytother Res 27: 152–155. https://doi.org/10.1002/ptr.4711 doi: 10.1002/ptr.4711
[41]
Annie S, Rajagopal P, Malini S (2005) Effect of Cassia auriculata Linn. root extract on cisplatin and gentamicin-induced renal injury. Phytomedicine 12: 555–560. https://doi.org/10.1016/j.phymed.2003.11.010 doi: 10.1016/j.phymed.2003.11.010
[42]
Jaydeokar AV, Bandawane DD, Bibave KH, et al. (2014) Hepatoprotective potential of Cassia auriculata roots on ethanol and antitubercular drug-induced hepatotoxicity in experimental models. Pharm Biol 52: 344–355. https://doi.org/10.3109/13880209.2013.837075 doi: 10.3109/13880209.2013.837075
[43]
Deshpande S, Kewatkar SM, Paithankar VV (2013) In-vitro antioxidant activity of different fraction of roots of Cassia auriculata Linn. Drug Invent Today 5: 164–168. https://doi.org/10.1016/j.dit.2013.05.006 doi: 10.1016/j.dit.2013.05.006
[44]
Salma B, Janhavi P, Muthaiah S, et al. (2020) Ameliorative efficacy of the Cassia auriculata root against high-fat-diet+ STZ-induced Type-2 diabetes in C57BL/6 mice. ACS Omega 6: 492–504. https://doi.org/10.1021/acsomega.0c04940 doi: 10.1021/acsomega.0c04940
[45]
Rao GN, Kumar PM, Dhandapani V, et al. (2000) Constituents of Cassia auriculata. Fitoterapia 71: 82–83. https://doi.org/10.4103/0250-474X.113546 doi: 10.4103/0250-474X.113546
[46]
Varshney S, Rizvi S, Gupta P (1973) Chemical and spectral studies of novel keto–alcohols from the leaves of Cassia auriculata. Planta Med 23: 363–369. https://doi.org/10.1055/s-0028-1099456 doi: 10.1055/s-0028-1099456
[47]
Murugan T, Wins JA, Murugan M (2013) Antimicrobial activity and phytochemical constituents of leaf extracts of Cassia auriculata. Indian J Pharm Sci 75: 122. https://doi.org/10.4103/0250-474X.113546 doi: 10.4103/0250-474X.113546
[48]
Gunathilake K, Ranaweera K, Rupasinghe H (2020) Optimization of polyphenols and carotenoids extraction from leaves of Cassia auriculata for natural health products. Asian Plant Res J 6: 14–25. https://doi.org/10.9734/APRJ/2020/v6i130118 doi: 10.9734/APRJ/2020/v6i130118
[49]
Abdulwaliyu I, Arekemase SO, Adudu JA, et al. (2019) Investigation of the medicinal significance of phytic acid as an indispensable anti-nutrient in diseases. Clin Nutr Exp 28: 42–61. https://doi.org/10.1016/j.yclnex.2019.10.002 doi: 10.1016/j.yclnex.2019.10.002
[50]
Bartolome AP, Villaseñor IM, Yang WC (2013) Bidens pilosa L.(Asteraceae): Botanical properties, traditional uses, phytochemistry, and pharmacology. Evidence-based Complementary Altern Med 2013: 340215. https://doi.org/10.1155/2013/340215 doi: 10.1155/2013/340215
[51]
Amsalu N, Asfaw Z (2020) Review of the antioxidant properties of wild edible plants in Ethiopia. Afr J Med Health Scis 19: 84–102. https://doi.org/10.5897/AJMHS2019.0082 doi: 10.5897/AJMHS2019.0082
[52]
Nagarani G, Abirami A, Siddhuraju P (2014) Food prospects and nutraceutical attributes of Momordica species: A potential tropical bioresources–A review. Food Sci Human Wellness 3: 117–126. https://doi.org/10.1016/j.fshw.2014.07.001 doi: 10.1016/j.fshw.2014.07.001
[53]
Ramakrishnan P, Kalakandan S, Pakkirisamy M (2018) Studies on positive and negative ionization mode of ESI-LC-MS/MS for screening of Phytochemicals on Cassia auriculata (Aavaram Poo). Pharm J 10: 457–462. https://doi.org/10.5530/pj.2018.3.75 doi: 10.5530/pj.2018.3.75
[54]
Rajkumar P, Selvaraj S, Suganya R, et al. (2016) GC-MS characterization of the anti-diabetic compounds from the flowers of Cassia auriculata (AVARAM): A structure based molecular docking studies. Int J Innov Res Sci Eng Technol 1: 85–93.
[55]
Bargah RK, Kushwaha A, Tirkey A, et al. (2020) In vitro antioxidant and antibacterial screening of flowers extract from Cassia auriculata Linn. Res J Pharm Technol 13: 2624–2628. https://doi.org/10.5958/0974-360X.2020.00466.7 doi: 10.5958/0974-360X.2020.00466.7
[56]
Sahoo J, Kamalaja T, Devi SS, et al. (2020) Nutritional composition of Cassia auriculata flower powder. J Pharmacogn Phytochem9: 867–870.
[57]
Girme A, Saste G, Chinchansure A, et al. (2020) Simultaneous determination of anthraquinone, flavonoids, and phenolic antidiabetic compounds from Cassia auriculata seeds by validated UHPLC based MS/MS method. Mass Spectrom Lett 11: 82–89.
[58]
Zhang Y, Nakamura S, Nakashima S, et al. (2015) Chemical structures of constituents from the seeds of Cassia auriculata. Tetrahedron 71: 6727–6732. https://doi.org/10.1016/j.tet.2015.07.045 doi: 10.1016/j.tet.2015.07.045
[59]
Raj JY, Peter MPJ, Joy V (2012) Chemical compounds investigation of Cassia auriculata seeds: A potential folklore medicinal plant. Asian J Plant Sci Res 2: 187–192.
[60]
Dave H, Ledwani L (2012) A review on anthraquinones isolated from Cassia species and their applications. IJNPR 3: 291–319.
[61]
Sivakumar V, Ilanhtiraiyan S, Ilayaraja K, et al. (2014) Influence of ultrasound on Avaram bark (Cassia auriculata) tannin extraction and tanning. Chem Eng Res Des 92: 1827–1833. https://doi.org/10.1016/j.cherd.2014.04.007 doi: 10.1016/j.cherd.2014.04.007
Yoshinari O, Igarashi K (2011) Anti-diabetic effect of pyroglutamic acid in type 2 diabetic Goto-Kakizaki rats and KK-A y mice. Br J Nutr 106: 995–1004. https://doi.org/10.1017/S0007114511001279 doi: 10.1017/S0007114511001279
[64]
Chou J, Liu R, Yu J, et al. (2018) Fasting serum α‑hydroxybutyrate and pyroglutamic acid as important metabolites for detecting isolated post-challenge diabetes based on organic acid profiles. J Chromatogr B 1100: 6–16. https://doi.org/10.1016/j.jchromb.2018.09.004 doi: 10.1016/j.jchromb.2018.09.004
[65]
Grioli S, Lomeo C, Quattropani M, et al. (1990) Pyroglutamic acid improves the age associated memory impairment. Fund Clin Pharmacol 4: 169–173. https://doi.org/10.1111/j.1472-8206.1990.tb00485.x doi: 10.1111/j.1472-8206.1990.tb00485.x
Gao K, Mu C-l, Farzi A, et al. (2020) Tryptophan metabolism: A link between the gut microbiota and brain. Adv Nutr 11: 709–723. https://doi.org/10.1093/advances/nmz127 doi: 10.1093/advances/nmz127
[68]
Li P, Yin Y-L, Li D, et al. (2007) Amino acids and immune function. Br J Nutr 98: 237–252. https://doi.org/10.1017/S000711450769936X doi: 10.1017/S000711450769936X
[69]
Nimalaratne C, Lopes-Lutz D, Schieber A, et al. (2011) Free aromatic amino acids in egg yolk show antioxidant properties. Food Chem 129: 155–161. https://doi.org/10.1016/j.foodchem.2011.04.058 doi: 10.1016/j.foodchem.2011.04.058
[70]
Ming X-F, Rajapakse AG, Carvas JM, et al. (2009) Inhibition of S6K1 accounts partially for the anti-inflammatory effects of the arginase inhibitor L-norvaline. BMC Cardiovasc Disor 9: 12. https://doi.org/10.1186/1471-2261-9-12 doi: 10.1186/1471-2261-9-12
[71]
Karak S, Nag G, De B (2017) Metabolic profile and β-glucuronidase inhibitory property of three species of Swertia. Rev Bras Farmacogn 27: 105–111. https://doi.org/10.1016/j.bjp.2016.07.007 doi: 10.1016/j.bjp.2016.07.007
[72]
Wakuda T, Azuma K, Saimoto H, et al. (2013) Protective effects of galacturonic acid-rich vinegar brewed from Japanese pear in a dextran sodium sulfate-induced acute colitis model. J Funct Foods 5: 516–523. https://doi.org/10.1016/j.jff.2012.10.010 doi: 10.1016/j.jff.2012.10.010
[73]
Suzuki M, Kajuu T (1983) Suppression of hepatic lipogenesis by pectin and galacturonic acid orally-fed at the separate timing from digestion-absorption of nutrients in rat. J Nutr Sci Vitaminol 29: 553–562. https://doi.org/10.3177/jnsv.29.553 doi: 10.3177/jnsv.29.553
[74]
Nguyen NK, Nguyen PB, Nguyen HT, et al. (2015) Screening the optimal ratio of symbiosis between isolated yeast and acetic acid bacteria strain from traditional kombucha for high-level production of glucuronic acid. LWT-Food Sci Technol 64: 1149–1155. https://doi.org/10.1016/j.lwt.2015.07.018 doi: 10.1016/j.lwt.2015.07.018
[75]
Biagi G, Piva A, Moschini M, et al. (2006) Effect of gluconic acid on piglet growth performance, intestinal microflora, and intestinal wall morphology. J Anim Sci 84: 370–378. https://doi.org/10.2527/2006.842370x doi: 10.2527/2006.842370x
[76]
Surman C, Vaudreuil C, Boland H, et al. (2020) L-threonic acid magnesium salt supplementation in ADHD: An open-label pilot study. J Diet Suppl 18: 119–131. https://doi.org/10.1080/19390211.2020.1731044 doi: 10.1080/19390211.2020.1731044
[77]
Banerjee S, Bhattacharjee P, Kar A, et al. (2019) LC–MS/MS analysis and network pharmacology of Trigonella foenum-graecum–A plant from Ayurveda against hyperlipidemia and hyperglycemia with combination synergy. Phytomedicine 60: 152944. https://doi.org/10.1016/j.phymed.2019.152944 doi: 10.1016/j.phymed.2019.152944
[78]
Vogt JA, Ishii-Schrade KB, Pencharz PB, et al. (2006) L-rhamnose and lactulose decrease serum triacylglycerols and their rates of synthesis, but do not affect serum cholesterol concentrations in men. J Nutr 136: 2160–2166.
[79]
Nagata Y, Mizuta N, Kanasaki A, et al. (2018) Rare sugars, d‐allulose, d‐tagatose and d‐sorbose, differently modulate lipid metabolism in rats. J Sci Food Agric 98: 2020–2026. https://doi.org/10.1002/jsfa.8687 doi: 10.1002/jsfa.8687
[80]
Oku T, Murata-Takenoshita Y, Yamazaki Y, et al. (2014) D-sorbose inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. Nutr Res 34: 961–967. https://doi.org/10.1016/j.nutres.2014.09.009 doi: 10.1016/j.nutres.2014.09.009
[81]
Yamada T, Hayashi N, Iida T, et al. (2014) Dietary D-sorbose decreases serum insulin levels in growing Sprague-Dawley rats. J Nutr Sci Vitaminol 60: 297–299. https://doi.org/10.3177/jnsv.60.297 doi: 10.3177/jnsv.60.297
[82]
Seri K, Sanai K, Matsuo N, et al. (1996) L-arabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals. Metabolism 45: 1368–1374. https://doi.org/10.1016/S0026-0495(96)90117-1 doi: 10.1016/S0026-0495(96)90117-1
[83]
Li Y, Pan H, Liu JX, et al. (2019) L-Arabinose inhibits colitis by modulating gut microbiota in mice. J Agric Food Chem 67: 13299–13306. https://doi.org/10.1021/acs.jafc.9b05829 doi: 10.1021/acs.jafc.9b05829
[84]
Roy S, Chikkerur J, Roy SC, et al. (2018) Tagatose as a potential nutraceutical: Production, properties, biological roles, and applications. J Food Sci 83: 2699–2709. https://doi.org/10.1111/1750-3841.14358 doi: 10.1111/1750-3841.14358
[85]
Chen Z, Chen J, Zhang W, et al. (2018) Recent research on the physiological functions, applications, and biotechnological production of D-allose. Appl Microbiol Biotechnol 102: 4269–4278. https://doi.org/10.1007/s00253-018-8916-6 doi: 10.1007/s00253-018-8916-6
[86]
Salkovic-Petrisic M, Osmanovic-Barilar J, Knezovic A, et al. (2014) Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin. Neuropharmacology 77: 68–80. https://doi.org/10.1016/j.neuropharm.2013.09.002 doi: 10.1016/j.neuropharm.2013.09.002
[87]
Park M-O, Lee B-H, Lim E, et al. (2016) Enzymatic process for high-yield turanose production and its potential property as an adipogenesis regulator. J Agric Food Chem 64: 4758–4764. https://doi.org/10.1021/acs.jafc.5b05849 doi: 10.1021/acs.jafc.5b05849
[88]
Chung J-Y, Kim Y-S, Kim Y, et al. (2017) Regulation of inflammation by sucrose isomer, Turanose, in raw 264.7 cells. J Cancer Prev 22: 195. https://doi.org/10.15430/JCP.2017.22.3.195 doi: 10.15430/JCP.2017.22.3.195
[89]
Kim E, Bae J, Lee J, et al. (2019) Purification and characterization of turanose, a sucrose isomer and its anti-inflammatory effects in dextran sulfate sodium (DSS)-induced colitis model. J Funct Foods 63: 103570. https://doi.org/10.1016/j.jff.2019.103570 doi: 10.1016/j.jff.2019.103570
[90]
Mizunoe Y, Kobayashi M, Sudo Y, et al. (2018) Trehalose protects against oxidative stress by regulating the Keap1–Nrf2 and autophagy pathways. Redox Biol 15: 115–124. https://doi.org/10.1016/j.redox.2017.09.007 doi: 10.1016/j.redox.2017.09.007
[91]
Laihia J, Kaarniranta K (2020) Trehalose for ocular surface health. Biomolecules 10: 809. https://doi.org/10.3390/biom10050809 doi: 10.3390/biom10050809
[92]
Thompson J, Neutel J, Homer K, et al. (2014) Evaluation of D‐ribose pharmacokinetics, dose proportionality, food effect, and pharmacodynamics after oral solution administration in healthy male and female subjects. J Clin Pharmacol 54: 546–554. https://doi.org/10.1002/jcph.241 doi: 10.1002/jcph.241
[93]
Addis P, Shecterle LM, Cyr JASt (2012) Cellular protection during oxidative stress: A potential role for D-ribose and antioxidants. J Diet Suppl 9: 178–182. https://doi.org/10.3109/19390211.2012.708715 doi: 10.3109/19390211.2012.708715
[94]
Croze ML, Soulage CO (2013) Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95: 1811–1827. https://doi.org/10.1016/j.biochi.2013.05.011 doi: 10.1016/j.biochi.2013.05.011
[95]
Corrado F, D'Anna R, Di Vieste G, et al. (2011) The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabetic Med 28: 972–975. https://doi.org/10.1111/j.1464-5491.2011.03284.x doi: 10.1111/j.1464-5491.2011.03284.x
[96]
Pintaudi B, Di Vieste G, Bonomo M (2016) The effectiveness of myo-inositol and D-chiro inositol treatment in type 2 diabetes. Int J Endocrinol 2016: 9132052. https://doi.org/10.1155/2016/9132052 doi: 10.1155/2016/9132052
[97]
Unfer V, Facchinetti F, Orrù B, et al. (2017) Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocr Connect 6: 647–658. https://doi.org/10.1530/EC-17-0243 doi: 10.1530/EC-17-0243
[98]
Benahmed AG, Gasmi A, Arshad M, et al. (2020) Health benefits of xylitol. Appl Microbiol Biotechnol 104: 109495. https://doi.org/10.1016/j.enzmictec.2019.109495 doi: 10.1016/j.enzmictec.2019.109495
[99]
Ur-Rehman S, Mushtaq Z, Zahoor T, et al. (2015) Xylitol: A review on bioproduction, application, health benefits, and related safety issues. Crit Rev Food Sci Nutr 55: 1514–1528. https://doi.org/10.1080/10408398.2012.702288 doi: 10.1080/10408398.2012.702288
[100]
Salli K, Lehtinen MJ, Tiihonen K, et al. (2019) Xylitol's health benefits beyond dental health: A comprehensive review. Nutrients 11: 1813. https://doi.org/10.3390/nu11081813 doi: 10.3390/nu11081813
[101]
Ching T-L, Haenen GR, Bast A (1993) Cimetidine and other H2 receptor antagonists as powerful hydroxyl radical scavengers. Chem-Biol Interact 86: 119–127. https://doi.org/10.1016/0009-2797(93)90116-G doi: 10.1016/0009-2797(93)90116-G
[102]
Saha BC, Racine FM (2011) Biotechnological production of mannitol and its applications. Appl Microbiol Biotechnol 89: 879–891. https://doi.org/10.1007/s00253-010-2979-3 doi: 10.1007/s00253-010-2979-3
[103]
den Hartog GJ, Boots AW, Adam-Perrot A, et al. (2010) Erythritol is a sweet antioxidant. Nutrition 26: 449–458. https://doi.org/10.1016/j.nut.2009.05.004 doi: 10.1016/j.nut.2009.05.004
[104]
Flint N, Hamburg NM, Holbrook M, et al. (2014) Effects of erythritol on endothelial function in patients with type 2 diabetes mellitus: A pilot study. Acta Diabetolo 51: 513–516. https://doi.org/10.1007/s00592-013-0534-2 doi: 10.1007/s00592-013-0534-2
[105]
Wen H, Tang B, Stewart AJ, et al. (2018) Erythritol attenuates postprandial blood glucose by inhibiting α-glucosidase. J Agric Food Chem 66: 1401–1407. https://doi.org/10.1021/acs.jafc.7b05033 doi: 10.1021/acs.jafc.7b05033
[106]
Wölnerhanssen BK, Meyer-Gerspach AC, Beglinger C, et al. (2020) Metabolic effects of the natural sweeteners xylitol and erythritol: A comprehensive review. Crit Rev Food Sci Nutr 60: 1986–1998. https://doi.org/10.1080/10408398.2019.1623757 doi: 10.1080/10408398.2019.1623757
[107]
Chauhan PS, Gupta KK, Bani S (2011) The immunosuppressive effects of Agyrolobium roseum and pinitol in experimental animals. Int Immunopharmacol 11: 286–291. https://doi.org/10.1016/j.intimp.2010.11.028 doi: 10.1016/j.intimp.2010.11.028
[108]
Kim HJ, Park KS, Lee SK, et al. (2012) Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus. Ann Nutr Metab 60: 1–5. https://doi.org/10.1159/000334834 doi: 10.1159/000334834
[109]
Dang NT, Mukai R, Yoshida K-i, et al. (2010) D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. Biosci, Biotechnol, Biochem 74: 1062–1067. https://doi.org/10.1271/bbb.90963 doi: 10.1271/bbb.90963
[110]
Hernández-Mijares A, Bañuls C, Peris JE, et al. (2013) A single acute dose of pinitol from a naturally-occurring food ingredient decreases hyperglycaemia and circulating insulin levels in healthy subjects. Food Chem 141: 1267–1272. https://doi.org/10.1016/j.foodchem.2013.04.042 doi: 10.1016/j.foodchem.2013.04.042
[111]
Gao Y, Zhang M, Wu T, et al. (2015) Effects of D-pinitol on insulin resistance through the PI3K/Akt signaling pathway in type 2 diabetes mellitus rats. J Agric Food Chem 63: 6019–6026. https://doi.org/10.1021/acs.jafc.5b01238 doi: 10.1021/acs.jafc.5b01238
[112]
Geethan PA, Prince PSM (2008) Antihyperlipidemic effect of D‐pinitol on streptozotocin‐induced diabetic wistar rats. J Biochem Mol Toxicol 22: 220–224. https://doi.org/10.1002/jbt.20218 doi: 10.1002/jbt.20218
[113]
Choi MS, Lee MK, Jung UJ, et al. (2009) Metabolic response of soy pinitol on lipid‐lowering, antioxidant and hepatoprotective action in hamsters fed‐high fat and high cholesterol diet. Mol Nutr Food Res 53: 751–759. https://doi.org/10.1002/mnfr.200800241 doi: 10.1002/mnfr.200800241
[114]
Sousa LGF, de Souza Cortez LUA, Evangelista JSAM, et al. (2020) Renal protective effect of pinitol in experimental diabetes. Eur J Pharmacol 880: 173130. https://doi.org/10.1016/j.ejphar.2020.173130 doi: 10.1016/j.ejphar.2020.173130
[115]
Lee E, Lim Y, Kwon SW, et al. (2019) Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. J Nutr Biochem 68: 33–41. https://doi.org/10.1016/j.jnutbio.2019.03.006 doi: 10.1016/j.jnutbio.2019.03.006
[116]
Vasaikar N, Mahajan U, Patil KR, et al. (2018) D-pinitol attenuates cisplatin-induced nephrotoxicity in rats: Impact on pro-inflammatory cytokines. Chem-Biol Interact 290: 6–11. https://doi.org/10.1016/j.cbi.2018.05.003 doi: 10.1016/j.cbi.2018.05.003
[117]
Sivakumar S, Palsamy P, Subramanian SP (2010) Attenuation of oxidative stress and alteration of hepatic tissue ultrastructure by D-pinitol in streptozotocin-induced diabetic rats. Free Radical Res 44: 668–678. https://doi.org/10.3109/10715761003733901 doi: 10.3109/10715761003733901
[118]
López-Domènech S, Bañuls C, de Marañón AM, et al. (2018) Pinitol alleviates systemic inflammatory cytokines in human obesity by a mechanism involving unfolded protein response and sirtuin 1. Clin Nutr 37: 2036–2044. https://doi.org/10.1016/j.clnu.2017.09.015 doi: 10.1016/j.clnu.2017.09.015
[119]
Kim JC, Shin JY, Shin DH, et al. (2005) Synergistic antiinflammatory effects of pinitol and glucosamine in rats. Phytother Res 19: 1048–1051. https://doi.org/10.1002/ptr.1788 doi: 10.1002/ptr.1788
[120]
Su H, Liu R, Chang M, et al. (2018) Effect of dietary alpha-linolenic acid on blood inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Eur J Nutr 57: 877–891. https://doi.org/10.1007/s00394-017-1386-2 doi: 10.1007/s00394-017-1386-2
[121]
Yue H, Qiu B, Jia M, et al. (2020) Effects of α-linolenic acid intake on blood lipid profiles: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 61: 2894–2910. https://doi.org/10.1080/10408398.2020.1790496 doi: 10.1080/10408398.2020.1790496
[122]
Yoshida Y, Niki E (2003) Antioxidant effects of phytosterol and its components. J Nutr Sci Vitaminol 49: 277–280. https://doi.org/10.3177/jnsv.49.277 doi: 10.3177/jnsv.49.277
[123]
Fatahi S, Kord-Varkaneh H, Talaei S, et al. (2019) Impact of phytosterol supplementation on plasma lipoprotein (a) and free fatty acid (FFA) concentrations: A systematic review and meta-analysis of randomized controlled trials. Nutr, Metab Cardiovas Dis 29: 1168–1175. https://doi.org/10.1016/j.numecd.2019.07.011 doi: 10.1016/j.numecd.2019.07.011
[124]
Umeno A, Horie M, Murotomi K, et al. (2016) Antioxidative and antidiabetic effects of natural polyphenols and isoflavones. Molecules 21: 708. https://doi.org/10.3390/molecules21060708 doi: 10.3390/molecules21060708
[125]
Habtemariam S, Varghese GK (2014) The antidiabetic therapeutic potential of dietary polyphenols. Curr Pharm Biotechnol 15: 391–400.
[126]
Vinayagam R, Jayachandran M, Xu B (2016) Antidiabetic effects of simple phenolic acids: A comprehensive review. Phytother Res 30: 184–199. https://doi.org/10.1002/ptr.5528 doi: 10.1002/ptr.5528
[127]
Dludla PV, Nkambule BB, Jack B, et al. (2019) Inflammation and oxidative stress in an obese state and the protective effects of gallic acid. Nutrients 11: 23. https://doi.org/10.3390/nu11010023 doi: 10.3390/nu11010023
[128]
Kahkeshani N, Farzaei F, Fotouhi M, et al. (2019) Pharmacological effects of gallic acid in health and diseases: A mechanistic review. Iran J Basic Med Sci 22: 225. https://doi.org/10.22038/ijbms.2019.32806.7897 doi: 10.22038/ijbms.2019.32806.7897
[129]
Badhani B, Sharma N, Kakkar R (2015) Gallic acid: A versatile antioxidant with promising therapeutic and industrial applications. RSC Adv 5: 27540–27557. https://doi.org/10.1039/C5RA01911G doi: 10.1039/C5RA01911G
[130]
Serra A, Macià A, Romero M-P, et al. (2012) Metabolic pathways of the colonic metabolism of flavonoids (flavonols, flavones and flavanones) and phenolic acids. Food Chem 130: 383–393. https://doi.org/10.1016/j.foodchem.2011.07.055 doi: 10.1016/j.foodchem.2011.07.055
[131]
Kumar N, Goel N (2019) Phenolic acids: Natural versatile molecules with promising therapeutic applications. Biotechnol Rep 24: e00370. https://doi.org/10.1016/j.btre.2019.e00370 doi: 10.1016/j.btre.2019.e00370
[132]
Abd El-Aziz TA, Mohamed RH, Pasha HF, et al. (2012) Catechin protects against oxidative stress and inflammatory-mediated cardiotoxicity in adriamycin-treated rats. Clin Exper Med 12: 233–240. https://doi.org/10.1007/s10238-011-0165-2 doi: 10.1007/s10238-011-0165-2
[133]
Shafabakhsh R, Milajerdi A, Reiner Ž, et al. (2020) The effects of catechin on endothelial function: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 60: 2369–2378. https://doi.org/10.1080/10408398.2019.1639037 doi: 10.1080/10408398.2019.1639037
[134]
Pedro AC, Maciel GM, Rampazzo Ribeiro V, et al. (2020) Fundamental and applied aspects of catechins from different sources: A review. Int J Food Sci Tech 55: 429–442. https://doi.org/10.1111/ijfs.14371 doi: 10.1111/ijfs.14371
[135]
Guo T, Song D, Cheng L, et al. (2019) Interactions of tea catechins with intestinal microbiota and their implication for human health. Food Sci Biotechnol 28: 1617–1625. https://doi.org/10.1007/s10068-019-00656-y doi: 10.1007/s10068-019-00656-y
[136]
Márquez Campos E, Jakobs L, Simon M-C (2020) Antidiabetic effects of flavan-3-ols and their microbial metabolites. Nutrients 12: 1592. https://doi.org/10.3390/nu12061592 doi: 10.3390/nu12061592
[137]
Bai L, Li X, He L, et al. (2019) Antidiabetic potential of flavonoids from traditional Chinese medicine: a review. Amer J Chin Med 47: 933–957. https://doi.org/10.1142/S0192415X19500496 doi: 10.1142/S0192415X19500496
[138]
Takahashi M, Miyashita M, Suzuki K, et al. (2014) Acute ingestion of catechin-rich green tea improves postprandial glucose status and increases serum thioredoxin concentrations in postmenopausal women. Br J Nutr 112: 1542–1550. https://doi.org/10.1017/S0007114514002530 doi: 10.1017/S0007114514002530
[139]
Eid HM, Ouchfoun M, Saleem A, et al. (2016) A combination of (+)-catechin and (−)-epicatechin underlies the in vitro adipogenic action of Labrador tea (Rhododendron groenlandicum), an antidiabetic medicinal plant of the Eastern James Bay Cree pharmacopeia. J Ethnopharmacol 178: 251–257. https://doi.org/10.1016/j.jep.2015.12.021 doi: 10.1016/j.jep.2015.12.021
[140]
Mrabti HN, Jaradat N, Fichtali I, et al. (2018) Separation, identification, and antidiabetic activity of catechin isolated from Arbutus unedo L. plant roots. Plants 7: 31. https://doi.org/10.3390/plants7020031 doi: 10.3390/plants7020031
[141]
Wang W, Sun C, Mao L, et al. (2016) The biological activities, chemical stability, metabolism and delivery systems of quercetin: A review. Trends Food Sci Technol 56: 21–38. https://doi.org/10.1016/j.tifs.2016.07.004 doi: 10.1016/j.tifs.2016.07.004
[142]
D'Andrea G (2015) Quercetin: A flavonol with multifaceted therapeutic applications? Fitoterapia 106: 256–271. https://doi.org/10.1016/j.fitote.2015.09.018 doi: 10.1016/j.fitote.2015.09.018
[143]
Lesjak M, Beara I, Simin N, et al. (2018) Antioxidant and anti-inflammatory activities of quercetin and its derivatives. J Funct Foods 40: 68–75. https://doi.org/10.1016/j.jff.2017.10.047 doi: 10.1016/j.jff.2017.10.047
[144]
Xu D, Hu M-J, Wang Y-Q, et al. (2019) Antioxidant activities of quercetin and its complexes for medicinal application. Molecules 24: 1123. https://doi.org/10.3390/molecules24061123 doi: 10.3390/molecules24061123
[145]
Zaplatic E, Bule M, Shah SZA, et al. (2019) Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer's disease. Life Sci 224: 109–119. https://doi.org/10.1016/j.lfs.2019.03.055 doi: 10.1016/j.lfs.2019.03.055
[146]
Patel RV, Mistry BM, Shinde SK, et al. (2018) Therapeutic potential of quercetin as a cardiovascular agent. Eur J Med Chem 155: 889–904. https://doi.org/10.1016/j.ejmech.2018.06.053 doi: 10.1016/j.ejmech.2018.06.053
[147]
Dabeek WM, Marra MV (2019) Dietary quercetin and kaempferol: Bioavailability and potential cardiovascular-related bioactivity in humans. Nutrients 11: 2288. https://doi.org/10.3390/nu11102288 doi: 10.3390/nu11102288
[148]
Bule M, Abdurahman A, Nikfar S, et al. (2019) Antidiabetic effect of quercetin: A systematic review and meta-analysis of animal studies. Food Chem Toxicol 125: 494–502. https://doi.org/10.1016/j.fct.2019.01.037 doi: 10.1016/j.fct.2019.01.037
[149]
Ahn J, Lee H, Kim S, et al. (2008) The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun 373: 545–549. https://doi.org/10.1016/j.bbrc.2008.06.077 doi: 10.1016/j.bbrc.2008.06.077
[150]
Nabavi SF, Russo GL, Daglia M, et al. (2015) Role of quercetin as an alternative for obesity treatment: you are what you eat! Food Chem 179: 305–310. https://doi.org/10.1016/j.foodchem.2015.02.006 doi: 10.1016/j.foodchem.2015.02.006
[151]
Mohammadi A, Kazemi S, Hosseini M, et al. (2019) Chrysin effect in prevention of acetaminophen-induced hepatotoxicity in rat. Chem Res Toxicol 32: 2329–2337. https://doi.org/10.1021/acs.chemrestox.9b00332 doi: 10.1021/acs.chemrestox.9b00332
[152]
Zhang Z, Li G, Szeto SS, et al. (2015) Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease. Free Radical Biol Med 84: 331–343. https://doi.org/10.1016/j.freeradbiomed.2015.02.030 doi: 10.1016/j.freeradbiomed.2015.02.030
[153]
Ramírez-Espinosa JJ, Saldaña-Ríos J, García-Jiménez S, et al. (2018) Chrysin induces antidiabetic, antidyslipidemic and anti-inflammatory effects in athymic nude diabetic mice. Molecules 23: 67. https://doi.org/10.3390/molecules23010067 doi: 10.3390/molecules23010067
[154]
Taslimi P, Kandemir FM, Demir Y, et al. (2019) The antidiabetic and anticholinergic effects of chrysin on cyclophosphamide‐induced multiple organ toxicity in rats: Pharmacological evaluation of some metabolic enzyme activities. J Biochem Mol Toxicol 33: e22313. https://doi.org/10.1002/jbt.22313 doi: 10.1002/jbt.22313
[155]
Malik EM, Müller CE (2016) Anthraquinones as pharmacological tools and drugs. Med Res Rev 36: 705–748. https://doi.org/10.1002/med.21391 doi: 10.1002/med.21391
[156]
Duval J, Pecher V, Poujol M, et al. (2016) Research advances for the extraction, analysis and uses of anthraquinones: A review. Ind Crop Prod 94: 812–833. https://doi.org/10.1016/j.indcrop.2016.09.056 doi: 10.1016/j.indcrop.2016.09.056
[157]
Fouillaud M, Caro Y, Venkatachalam M, et al. (2018) Anthraquinones, In: Nollet L, Gutierrez-Uribe J (Eds.), Phenolic compounds in food, Boca Raton: CRC Press, 131–172.
[158]
Li Y, Jiang J-G (2018) Health functions and structure–activity relationships of natural anthraquinones from plants. Food Funct 9: 6063–6080. https://doi.org/10.1039/C8FO01569D doi: 10.1039/C8FO01569D
[159]
Yen G-C, Duh P-D, Chuang D-Y (2000) Antioxidant activity of anthraquinones and anthrone. Food Chem 70: 437–441. https://doi.org/10.1016/S0308-8146(00)00108-4 doi: 10.1016/S0308-8146(00)00108-4
[160]
Li X, Chu S, Liu Y, et al. (2019) Neuroprotective effects of anthraquinones from rhubarb in central nervous system diseases. Evidence-Based Complementary Altern Med 2019: 3790728. https://doi.org/10.1155/2019/3790728 doi: 10.1155/2019/3790728
[161]
Chen Db, Gao Hw, Peng C, et al. (2020) Quinones as preventive agents in Alzheimer's diseases: Focus on NLRP3 inflammasomes. J Pharm Pharmacol 72: 1481–1490. https://doi.org/10.1111/jphp.13332 doi: 10.1111/jphp.13332
[162]
Chien S-C, Wu Y-C, Chen Z-W, et al. (2015) Naturally occurring anthraquinones: Chemistry and therapeutic potential in autoimmune diabetes. Evidence-Based Complementary Altern Med 2015: 357357. https://doi.org/10.1155/2015/357357 doi: 10.1155/2015/357357
[163]
Zhao XY, Qiao GF, Li BX, et al. (2009) Hypoglycaemic and hypolipidaemic effects of emodin and its effect on L-type calcium channnels in dyslipidaemic-diabetic rats. Clin Exp Pharmacol Physiol 36: 29–34. https://doi.org/10.1111/j.1440-1681.2008.05051.x doi: 10.1111/j.1440-1681.2008.05051.x
[164]
Mishra SK, Tiwari S, Shrivastava A, et al. (2014) Antidyslipidemic effect and antioxidant activity of anthraquinone derivatives from Rheum emodi rhizomes in dyslipidemic rats. J Nat Med 68: 363–371. https://doi.org/10.1007/s11418-013-0810-z doi: 10.1007/s11418-013-0810-z
[165]
Li P, Lu Q, Jiang W, et al. (2017) Pharmacokinetics and pharmacodynamics of rhubarb anthraquinones extract in normal and disease rats. Biomed Pharmacother 91: 425–435. https://doi.org/10.1016/j.biopha.2017.04.109 doi: 10.1016/j.biopha.2017.04.109
[166]
Dalirfardouei R, Karimi G, Jamialahmadi K (2016) Molecular mechanisms and biomedical applications of glucosamine as a potential multifunctional therapeutic agent. Life Sci 152: 21–29. https://doi.org/10.1016/j.lfs.2016.03.028 doi: 10.1016/j.lfs.2016.03.028
[167]
Shintani T, Yamazaki F, Katoh T, et al. (2010) Glucosamine induces autophagy via an mTOR-independent pathway. Biochem Biophys Res Commun 391: 1775–1779. https://doi.org/10.1016/j.bbrc.2009.12.154 doi: 10.1016/j.bbrc.2009.12.154
[168]
Lee JH, Jia Y, Thach TT, et al. (2017) Hexacosanol reduces plasma and hepatic cholesterol by activation of AMP-activated protein kinase and suppression of sterol regulatory element-binding protein-2 in HepG2 and C57BL/6J mice. Nutr Res 43: 89–99. https://doi.org/10.1016/j.nutres.2017.05.013 doi: 10.1016/j.nutres.2017.05.013
[169]
Hsu C, Shih H, Chang Y, et al. (2015) The beneficial effects of tetracosanol on insulin-resistance by insulin receptor kinase sensibilisation. J Funct Foods 14: 174–182. https://doi.org/10.1016/j.jff.2015.01.033 doi: 10.1016/j.jff.2015.01.033
[170]
Ninh The S (2017) A review on the medicinal plant Dalbergia odorifera species: Phytochemistry and biological activity. Evidence-Based Complementary Altern Med 2017: 7142370. https://doi.org/10.1155/2017/7142370 doi: 10.1155/2017/7142370
[171]
Lee D-S, Jeong G-S (2014) Arylbenzofuran isolated from Dalbergia odorifera suppresses lipopolysaccharide-induced mouse BV2 microglial cell activation, which protects mouse hippocampal HT22 cells death from neuroinflammation-mediated toxicity. Eur J Pharmacol 728: 1–8. https://doi.org/10.1016/j.ejphar.2013.12.041 doi: 10.1016/j.ejphar.2013.12.041
Table 1.
Model parameters based on reference [19] used in the numerical simulation for Botswana and Zimbabwe. The values in parentheses refer to Zimbabwe.